| Dosimetry for treatment with radiolabelled somatostatin analogues. A review. | |
| | |
MedLine Citation:
|
PMID: 20168285 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Peptide Receptor Radionuclide Therapy (PRRT) has proven its efficacy in the treatment of neuroendocrine and other somatostatin receptor expressing tumours (SR-tumours). Several clinical trials have confirmed that adverse effects are represented by possible renal impairment, which is the major concern, and low but not absent hematological toxicity. High kidney irradiation is a constant, despite the sparing of dose obtained by renal protectors. Hematological toxicity, although low, needs to be monitored. The clinical and dosimetry results collected in more than a decade have recognized weak points to unravel, increased knowledge, offering new views. When planning therapy with radiopeptides, the large patients' variability as for biodistribution and tumour uptake must be taken into account in order to tailor the therapy, or at least to avoid foreseeable gross treatments. Reliable and personalized dosimetry is more and more requested. This paper reviews through the literature the methods to study the biokinetics, the dosimetry outcomes, some clue information and correlations obtained once applying the radiobiological models. Special focus is given on recent improvements and indications for critical organ protection that light up challenging perspectives for PRRT. |
| | |
Authors:
|
M Cremonesi; F Botta; A Di Dia; M Ferrari; L Bodei; C De Cicco; A Rossi; M Bartolomei; R Mei; S Severi; M Salvatori; G Pedroli; G Paganelli |
Related Documents
:
|
6282425 - Factors affecting the survival of patients with lacrimal gland tumours. 7850325 - Superficial bladder cancer: for how long should a tumour-free patient have check cystos... 18644285 - Intratumoural injection of gamma leinolenic acid in malignant gliomas. 1319095 - Rhabdomyosarcomas developing in association with mediastinal germ cell tumours. 7064735 - Combination chemotherapy of advanced non-hodgkin's lymphoma with adriamycin, vincristin... 21439815 - High serum angiogenin at diagnosis predicts for failure on long-term treatment response... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology Volume: 54 ISSN: 1824-4785 ISO Abbreviation: Q J Nucl Med Mol Imaging Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-19 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101213861 Medline TA: Q J Nucl Med Mol Imaging Country: Italy |
Other Details:
|
Languages: eng Pagination: 37-51 Citation Subset: IM |
Affiliation:
|
Medical Physics, European Institute of Oncology, Milan, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but...
Next Document: Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.